In this issue:
MRD by flow cytometry vs. ASO-RQ-PCR in MM treated with lenalidomide maintenance
Long-term follow-up of tandem autologous-allogeneic HCT for MM
Busulfan + melphalan vs. melphalan conditioning before autologous HCT in MM
MGUS risk for relatives of MM patients
Anti-BCMA CAR T-cell therapy in relapsed/refractory MM
All-oral ixazomib, cyclophosphamide and dexamethasone for relapsed/ refractory MM
Daratumumab, bortezomib, cyclophosphamide and dexamethasone for MM
Autologous SCT, consolidation and maintenance therapy in MM
MM in patients aged ≤30 years
Cost of peripheral neuropathy associated with MM treatment
Please login below to download this issue (PDF)